Journal: Cell Reports Medicine

Article Title: Interferon-γ-stimulated antigen-presenting cancer-associated fibroblasts hinder neoadjuvant chemoimmunotherapy efficacy in lung cancer

doi: 10.1016/j.xcrm.2025.102017

Figure Lengend Snippet:

Article Snippet: Control cultures were carried out in the presence of control human anti-β-Gal-hIgG4 (S228P; InvivoGen) at 10 μg/mL.

Techniques: Recombinant, Staining, Purification, In Vivo, Control, Protease Inhibitor, Activation Assay, Membrane, Modification, Bicinchoninic Acid Protein Assay, Immunohistochemical staining, Enzyme-linked Immunosorbent Assay, Cell Isolation, Sequencing, Negative Control, shRNA, Software

Journal: Acta pharmaceutica Sinica. B

Article Title: Anti-PD-L1 antibody enhances curative effect of cryoablation via antibody-dependent cell-mediated cytotoxicity mediating PD-L1 high CD11b + cells elimination in hepatocellular carcinoma.

doi: 10.1016/j.apsb.2022.08.006

Figure Lengend Snippet: Figure 5 Anti-PD-L1 antibody triggered NK cell-mediated ADCC effect to eliminating CD11bþ myeloid cells. (A, B) Representative flow cytometry plots of CD49bþ NK cells gated on CD45þ cells and granzyme Bþ cells gated on NK cells in all groups. (C) Flow cytometric quantification of CD49bþ (NK) population, and expression of granzyme Bþ populations in all groups. n Z 6 for each group, *P < 0.05, **P < 0.01, ***P < 0.001. ns, no significant difference, t-tests. All data are mean SEM. (D) H22 cells were inoculated subcutaneously into BALB/c mice. Twelve days later, cryoablation or microwave-ablation was proceeded, with corresponding antibody being infused via tail injection every 3 days. ADCC blocking assay employed by anti-mouse CD16 neutralizing antibody. Anti-mouse IgG was used as negative control. Tumor volume was shown. n Z 6 for each groups, *P < 0.05, **P < 0.01, ***P < 0.001. ns, no significant difference, t-tests. All data are mean SEM. (E) Immunofluorescence staining of tumor tissue sections. CD11b were stained with Alexa Fluor 647, CD49b was stained with Alexa Fluor 488, Tunel was stained by Alexa Fluor 594. Scale bar Z 20 mm.

Article Snippet: For testing the affinity between PD-L1 antibodies and mouse CD16, atezolizumab (tecentriq), Avelumab (Bavencio), Mutant AntiPD-L1-mIgG1e3 (InvivoGen, hpdl1-mab15, San Diego, CA, USA), Mouse IgG1 Isotype Control (R&D, MAB002, Emeryville, CA, USA), Human IgG1 (N298A) isotype control (InvivoGen, bgalmab12, San Diego, CA, USA) were labeled with FITC fluorescence using the ZENON ALEXA FLUOR 488 MOUSE IG 1 KIT (ThermoFisher, Z25002, Carlsbad, CA, USA) as recommended by the manufacturer.

Techniques: Cytometry, Expressing, Injection, Blocking Assay, Negative Control, Staining, TUNEL Assay

Journal: Acta pharmaceutica Sinica. B

Article Title: Anti-PD-L1 antibody enhances curative effect of cryoablation via antibody-dependent cell-mediated cytotoxicity mediating PD-L1 high CD11b + cells elimination in hepatocellular carcinoma.

doi: 10.1016/j.apsb.2022.08.006

Figure Lengend Snippet: Figure 8 Bavencio induced enhanced ADCC effect than mutant Fc antibodies in eliminating human HCC infiltrating PD-L1þ CD33bþ myeloid cells in vitro. (A) Surgically resected human HCC tumor and autologous PBMCs were collected from three individuals. Three different parts of each tumor was collected considering intratumoral heterogeneity. CD33þ myeloid cells and CD45- tumor cells from tumor were sorted as target cells, and CD56þ NK cells from PBMCs for effector cells. NK cells were co-cultured with target cells as previously described. (B) Quantification of flow cytometry revealed PD-L1 expressed on tumor cell, T cell and myeloid cells in tumor microenvironment for three patients. (C) Representative images for IFN-g Elispot assay revealed the different antibodies induced ADCC effect. Target cells derived from one of the three part of tumor in HCC-1 candidate. PHA was regarded as positive control, no antibodies added and Isotype IgG1 was control group. (D) The number of IFN-g spots/1 105 cells in each group. n Z 3 for each patient, *P < 0.05, **P < 0.01, ***P < 0.001. ns, no significant difference, t- tests. All data are mean SEM.

Article Snippet: For testing the affinity between PD-L1 antibodies and mouse CD16, atezolizumab (tecentriq), Avelumab (Bavencio), Mutant AntiPD-L1-mIgG1e3 (InvivoGen, hpdl1-mab15, San Diego, CA, USA), Mouse IgG1 Isotype Control (R&D, MAB002, Emeryville, CA, USA), Human IgG1 (N298A) isotype control (InvivoGen, bgalmab12, San Diego, CA, USA) were labeled with FITC fluorescence using the ZENON ALEXA FLUOR 488 MOUSE IG 1 KIT (ThermoFisher, Z25002, Carlsbad, CA, USA) as recommended by the manufacturer.

Techniques: Mutagenesis, In Vitro, Cell Culture, Cytometry, Enzyme-linked Immunospot, Derivative Assay, Positive Control, Control

Journal: bioRxiv

Article Title: Dysplastic Epithelial Repair Propagates Chronic Pathology Through the Paracrine Transformation of Pulmonary Fibroblasts

doi: 10.64898/2026.04.02.716135

Figure Lengend Snippet: ( A ) Quantified levels of IL-1α from naïve fibroblast (Naïve fibro), inflammatory fibroblast (Inflam fibro), and ectopic basal cell (Basal) conditioned media as determined by ELISA. ( B ) Saa3 and Ccl2 gene expression by RT-qPCR for fibroblasts cultured on 0.5kPa plates and treated with a 5-fold titration of IL-1α added to control media, including the level determined in (A). ( C ) Graphic illustrating the strategy used to deplete conditioned media of endogenous IL-1α with antibodies, magnetic beads, and column-based separation. ( D ) Saa3 and Ccl2 gene expression by RT-qPCR for fibroblasts cultured on 0.5kPa plates in control or conditioned media depleted using IgG (CTRL IgG or CM IgG) or IL-1α nAb (CTRL nAB, CM nAb) and supplemented with additional IL-1α nAb after depletion (+Spike). [(B) and (D)] Data shows mean fold change ± SD and are pooled from 3 independent experiments (n=3 mice). P values were calculated using either (B) a ratio paired t -test or (D) a one-way ANOVA with post-hoc Turkey multiple comparison test: * P < 0.05, ** P < 0.01, **** P < 0.0001, ns: not significant.

Article Snippet: The working concentration for the following reagents can be found in the text and figure legends: Human IL-1RA Recombinant Protein (IL1Ra) (PeproTech®, 200-01RA), Mouse IL-1 alpha Recombinant Protein, (PeproTech®, 211-11A), Mouse IL-1α Neutralizing Antibody (Invivogen, Anti-mIL-1α-mIgG1 clone 6H7, mIL-1α-mab9-02), Recombinant Mouse IgG1 Isotype Control Antibody (Invivogen, Anti-β-Gal-mIgG1 clone T9C6, bgal-mab9-02), Human TGF-β 1 Recombinant Protein (PeproTech®, 100-21), Human GDF15 Recombinant Protein (PeproTech®, 120-28C), Human VEGF Recombinant Protein (PeproTech®, 450-32), Human OPN Recombinant Protein (PeproTech®, 120-35), Murine CXCL1 Recombinant Protein (PeproTech®, 250-11), Human IGFBP3 Recombinant Protein (PeproTech®, 100-08), Human TNFRSF11B Recombinant Protein (PeproTech®, 450-14), Murine CXCL5 Recombinant Protein (PeproTech®, 250-17), and Muring CCL20 Recombinant Protein (PeproTech®, 250-27).

Techniques: Enzyme-linked Immunosorbent Assay, Gene Expression, Quantitative RT-PCR, Cell Culture, Titration, Control, Magnetic Beads, Comparison